Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.

① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.

cls.cnDec 24 04:16 ET

Notice highlights | China Eastern Airlines Corporation's passenger traffic increased by about 20% in November; CTIHK expects an annual Net income growth of no less than 30%.

In November, CHINA SOUTH AIR's passenger capacity input rose by 7.18% year-on-year; passenger turnover increased by 15.17% year-on-year; China Eastern Airlines' passenger capacity input increased by 9.19% year-on-year; passenger turnover increased by 20.86% year-on-year.

cls.cnDec 16 19:17 ET

HBM HOLDINGS-B (02142.HK) has reached a development cooperation with Candid on the next-generation T cell connector.

On December 16, 2023, HBM HOLDINGS-B (02142.HK) announced that its wholly-owned subsidiary, Nona Bioscience (Suzhou) Co., Ltd. (Nona Bioscience), has reached a research collaboration and licensing agreement with Candid Therapeutics, Inc. (Candid) to develop the next-generation T cell connector. According to the terms of the agreement, Nona Bioscience is entitled to receive an upfront payment and potential milestone payments of up to 0.32 billion USD. Candid will be responsible for all subsequent development work on the product. Candid Therapeutics, Inc. is

Gelonghui FinanceDec 16 07:07 ET

Express News | Hbm Holdings - Nona Biosciences Will Be Eligible to Receive Upfront and Potential Milestone Payments of up to US$320 Mln

ReutersDec 16 07:02 ET

Express News | Hbm Holdings - Unit Entering T-Cell Engager Discovery Collaboration With Candid Therapeutics

ReutersDec 16 07:02 ET

The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!

Industry pessimistic expectations may improve.

Gelonghui FinanceDec 8 23:10 ET